Domestic markets, new product launches to drive FY22 earnings for Alkem
The mainstay India business continues to do well, with boost coming from covid-led sales. Analysts say that the company has seen a good pick-up in 1QFY22 sales of vitamins/minerals, antacids, antibiotics, pain relief medicines, among others
Alkem Labs sees huge sales momentum of anti-infectives in Q1FY22
Secondary infections due to bacteria and fungus have gained traction pushing up sales; healthy momentum in chronic therapies and increased usage of vitamins, nutrients and minerals act as growth triggers
Earnings Call for Q4FY21 of Alkem Laboratories
Conference Call with Alkem Laboratories Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.
Alkem Laboratories Ltd - 539523 - Updates On Record Date/Cut Off Date
This is with reference to our earlier intimation letter dated today for outcome of the Board Meeting and intimation of record date, kindly note that the record date for the purpose of 47th Annual General Meeting be referred to as the cut-off date i.e 20th August, 2021. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Restructuring
This is to inform you that the Company at its meeting held today i.e. 25th May, 2021, has approved the restructuring of the Company's Subsidiaries in USA. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Para A of Part A of Schedule III of the aforesaid Regulations, is attached as per 'Annexure A'. A copy of the said disclosure will be made available on the Company's website as well in accordance with Regulation 30(8) of the aforesaid Regulations. This is for your information and record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of Directors at its meeting held today i.e. 25th May, 2021, has, inter alia based on recommendation of Nomination and Remuneration Committee and subject to approval of shareholders at the ensuing Annual General Meeting, approved the re-appointment of Dr. Dheeraj Sharma as an Independent Director of the Company for the second term of five (5) consecutive years with effect from 26th May, 2022 upto 25th May, 2027. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 26th March, 2021 regarding closure of trading window (for the purpose of financial results for the quarter and year ended 31st March, 2021) starting from 30th March, 2021 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2021 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter and year ended 31st March, 2021 having been communicated to the Stock Exchanges, today i.e. 25th May, 2021, the trading window shall open on 28th May, 2021. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q4FY21 and FY21 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Corporate Action - Fixes Record Date For Annual General Meeting And Payment Of Dividend
The Board of Directors at its meeting held today i.e. 25th May, 2021, has, inter alia fixed 20th August, 2021 as the record date for the purpose of the Annual General Meeting and 10th August, 2021 as the record date for the payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 01st September 2021. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Corporate Action-Board approves Dividend
The Board of Directors at its meeting held today i.e. 25th May, 2021, has, inter alia: 1. recommended a final dividend of Rs. 5/- (Rupees Five only) per equity share of Rs. 2/- each for the financial year ended 31st March, 2021, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 47th Annual General Meeting of the Company shall be held on 27th August, 2021 and the record date for the purpose of the said Annual General Meeting has been fixed as 20th August, 2021. 3. fixed 10th August, 2021 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 01st September 2021. Kindly take the same on record.